UnitedHealthcare is the largest U.S. commercial insurer. Coverage of GLP-1 medications varies significantly by employer plan (UHC commercial) and government plan (UHC Medicare Advantage, UHC Medicaid).
Type 2 diabetes coverage
Generally covered for T2D indication (Ozempic, Mounjaro, Trulicity). Typical copay $25–$100/month with PA.
Weight management coverage
Variable. Many UHC commercial plans cover Wegovy and Zepbound for weight indication with PA; some exclude weight management entirely as an employer-elected exclusion. Check your specific plan documents.
Cardiovascular indication coverage
Many UHC plans cover Wegovy under the cardiovascular indication (March 2024 FDA approval) with PA criteria matching SELECT enrollment: BMI ≥27 + established CVD.
OSA indication coverage
Coverage of Zepbound for OSA (December 2024 FDA approval) is being added to UHC formularies as of 2026; verify with your plan.
Prior authorization criteria (typical)
Typical PA criteria: BMI ≥30 or BMI ≥27 with weight-related comorbidity; documented attempt at lifestyle modification 3–6 months; some plans require step therapy.
If your plan excludes weight-management drugs
Consider the CV or OSA indication if you qualify; appeal denials with detailed medical necessity documentation; consider cash-pay compounded GLP-1 as alternative.
How to verify
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
Cash-pay alternative
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. NexLife, our editorial pick, lists compounded semaglutide at $95–$109 and tirzepatide at $115–$129 a month depending on plan length (prices as of November 6, 2026); see the NexLife review.